News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,374 Results
Type
Article (13893)
Company Profile (295)
Press Release (246186)
Section
Business (79330)
Career Advice (153)
Deals (13180)
Drug Delivery (32)
Drug Development (50289)
Employer Resources (31)
FDA (5670)
Job Trends (5114)
News (144074)
Policy (10016)
Tag
Academia (901)
Alliances (21469)
Alzheimer's disease (736)
Approvals (5645)
Artificial intelligence (63)
Bankruptcy (97)
Best Places to Work (4499)
Biotechnology (242)
Breast cancer (66)
Cancer (699)
Cardiovascular disease (62)
Career advice (133)
CAR-T (57)
Cell therapy (178)
Clinical research (39819)
Collaboration (239)
Compensation (99)
COVID-19 (1002)
C-suite (68)
Cystic fibrosis (66)
Data (798)
Diabetes (73)
Diagnostics (1201)
Earnings (28978)
Events (46855)
Executive appointments (193)
FDA (5964)
Funding (252)
Gene editing (55)
Gene therapy (148)
GLP-1 (301)
Government (1064)
Healthcare (6532)
Infectious disease (1037)
Inflammatory bowel disease (94)
IPO (7182)
Job creations (859)
Job search strategy (128)
Layoffs (184)
Legal (1374)
Lung cancer (111)
Manufacturing (74)
Medical device (2553)
Medtech (2554)
Mergers & acquisitions (6102)
Metabolic disorders (225)
Neuroscience (946)
NextGen Class of 2024 (1999)
Non-profit (844)
Northern California (951)
Obesity (124)
Opinion (91)
Parkinson's disease (61)
Patents (52)
People (24989)
Pharmaceutical (50)
Phase I (14009)
Phase II (18525)
Phase III (11737)
Pipeline (324)
Postmarket research (846)
Preclinical (5929)
Radiopharmaceuticals (205)
Rare diseases (169)
Real estate (1409)
Regulatory (8207)
Research institute (930)
Southern California (868)
Startups (1964)
United States (7654)
Vaccines (160)
Weight loss (76)
Date
Today (1)
Last 7 days (419)
Last 30 days (2158)
Last 365 days (20728)
2024 (19058)
2023 (22412)
2022 (26825)
2021 (27806)
2020 (23361)
2019 (16225)
2018 (11740)
2017 (13750)
2016 (11839)
2015 (14354)
2014 (10398)
2013 (7486)
2012 (7534)
2011 (7618)
2010 (7429)
Location
Africa (147)
Asia (16835)
Australia (2841)
California (2158)
Canada (718)
China (166)
Colorado (82)
Connecticut (86)
Europe (36254)
Florida (232)
Georgia (62)
Illinois (126)
Indiana (54)
Kansas (55)
Maryland (300)
Massachusetts (1712)
Michigan (48)
Minnesota (94)
New Jersey (549)
New York (615)
North Carolina (399)
Northern California (951)
Ohio (79)
Pennsylvania (429)
South America (208)
Southern California (868)
Texas (232)
Washington State (221)
260,374 Results for "disarm therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics’ Founders to Company’s Scientific Advisory Board
November 13, 2024
·
6 min read
Drug Development
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a ‘diSArm’ Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus
Armata Pharmaceuticals, Inc. today announced that the first patient has been dosed in the Phase 2a portion of the Company’s diSArm study of AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Initiation of the Phase 2a portion of the study follows Data Review Committee (DRC) review of positive safety and tolerability data from the Phase 1b portion.
September 26, 2023
·
6 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Deals
Lilly Announces Agreement to Acquire Disarm Therapeutics
Acquisition expands Lilly’s R&D efforts in pain and neurodegeneration with the addition of Disarm’s promising preclinical SARM1 programs for axonal degeneration [15-October-2020] INDIANAPOLIS and CAMBRIDGE, Mass. , Oct. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a definitive agreement to acquire Disarm Therapeutics, a privately-he
October 15, 2020
·
5 min read
Drug Development
Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a ‘diSArm’ Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus
Armata Pharmaceuticals, Inc. today announced that the first patient has been dosed in the company’s Phase 1b/2a clinical trial (‘diSArm’) of AP-SA02, which is being developed for the treatment of complicated Staphylococcus aureus bacteremia.
May 23, 2022
·
5 min read
Pharm Country
Disarming the immune system’s lethal lung response
Caryl Boies professor of cancer research at Cold Spring Harbor Laboratory (CSHL), and his team have found a drug candidate that can prevent lethal lung inflammation in mice by inhibiting a protein called PTP1B.
September 23, 2022
·
2 min read
Drug Development
Research Roundup: Disarming Overactive Neutrophils in the Lungs and More
This week, researchers published results from studies on treatments in lung disease, Alzheimer’s and various cancers. Here’s a look at that and more.
September 29, 2022
·
4 min read
·
Katherine Davis
Deals
Eli Lilly Acquires Disarm Therapeutics in an Effort to Solve Axonal Degeneration
Eli Lilly is betting on a new approach to axonal degeneration, announcing a definitive agreement to acquire Disarm Therapeutics, a privately-held biotech company committed to solving this mystery.
October 15, 2020
·
2 min read
·
Heather McKenzie
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Layoffs
Spero Therapeutics to Lay Off 39% of Employees
Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.
October 30, 2024
·
1 min read
·
Angela Gabriel
1 of 26,038
Next